PepGen (PEPG) Competitors $1.59 +0.12 (+8.16%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.59 0.00 (0.00%) As of 05/2/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PEPG vs. ANNX, OCGN, YMAB, GOSS, DMAC, IVA, MDWD, ELDN, CRDF, and VYGRShould you be buying PepGen stock or one of its competitors? The main competitors of PepGen include Annexon (ANNX), Ocugen (OCGN), Y-mAbs Therapeutics (YMAB), Gossamer Bio (GOSS), DiaMedica Therapeutics (DMAC), Inventiva (IVA), MediWound (MDWD), Eledon Pharmaceuticals (ELDN), Cardiff Oncology (CRDF), and Voyager Therapeutics (VYGR). These companies are all part of the "pharmaceutical products" industry. PepGen vs. Annexon Ocugen Y-mAbs Therapeutics Gossamer Bio DiaMedica Therapeutics Inventiva MediWound Eledon Pharmaceuticals Cardiff Oncology Voyager Therapeutics PepGen (NASDAQ:PEPG) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation. Do analysts rate PEPG or ANNX? PepGen presently has a consensus price target of $10.33, indicating a potential upside of 549.90%. Annexon has a consensus price target of $18.67, indicating a potential upside of 847.55%. Given Annexon's stronger consensus rating and higher probable upside, analysts clearly believe Annexon is more favorable than PepGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Annexon 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in PEPG or ANNX? Annexon received 35 more outperform votes than PepGen when rated by MarketBeat users. However, 80.00% of users gave PepGen an outperform vote while only 77.46% of users gave Annexon an outperform vote. CompanyUnderperformOutperformPepGenOutperform Votes2080.00% Underperform Votes520.00% AnnexonOutperform Votes5577.46% Underperform Votes1622.54% Does the media prefer PEPG or ANNX? In the previous week, PepGen had 1 more articles in the media than Annexon. MarketBeat recorded 1 mentions for PepGen and 0 mentions for Annexon. PepGen's average media sentiment score of 1.68 beat Annexon's score of 1.67 indicating that PepGen is being referred to more favorably in the media. Company Overall Sentiment PepGen Very Positive Annexon Very Positive Which has more volatility and risk, PEPG or ANNX? PepGen has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Annexon has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Is PEPG or ANNX more profitable? Annexon's return on equity of -38.99% beat PepGen's return on equity.Company Net Margins Return on Equity Return on Assets PepGenN/A -60.17% -48.88% Annexon N/A -38.99%-33.90% Which has stronger earnings & valuation, PEPG or ANNX? Annexon is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPepGenN/AN/A-$78.63M-$2.84-0.56AnnexonN/AN/A-$134.24M-$1.02-1.93 Do institutionals & insiders hold more shares of PEPG or ANNX? 58.0% of PepGen shares are held by institutional investors. 4.6% of PepGen shares are held by insiders. Comparatively, 12.7% of Annexon shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryAnnexon beats PepGen on 8 of the 15 factors compared between the two stocks. Get PepGen News Delivered to You Automatically Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PEPG vs. The Competition Export to ExcelMetricPepGenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.03M$6.85B$5.56B$8.03BDividend YieldN/A2.91%5.07%4.23%P/E Ratio-0.537.5022.7718.87Price / SalesN/A259.05405.66106.84Price / CashN/A65.8538.1834.62Price / Book0.356.566.794.34Net Income-$78.63M$143.63M$3.22B$248.06M7 Day Performance3.92%3.35%3.36%3.18%1 Month Performance27.20%10.29%6.91%8.28%1 Year Performance-88.80%-3.67%16.16%5.04% PepGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PEPGPepGen2.926 of 5 stars$1.59+8.2%$10.33+549.9%-88.8%$52.03MN/A-0.5330Positive NewsGap UpANNXAnnexon2.0826 of 5 stars$1.89+0.5%$18.67+887.7%-59.6%$207.35MN/A-1.8060Positive NewsOCGNOcugen1.0335 of 5 stars$0.71-1.3%$6.33+792.0%-42.5%$207.33M$4.06M-3.9480News CoverageYMABY-mAbs Therapeutics3.8479 of 5 stars$4.23+3.2%$17.40+311.3%-74.3%$205.29M$87.69M-7.83150Upcoming EarningsShort Interest ↓News CoverageGOSSGossamer Bio4.0503 of 5 stars$0.88-8.5%$7.50+755.8%+59.5%$199.14M$114.70M-2.74180Upcoming EarningsNews CoverageDMACDiaMedica Therapeutics1.6193 of 5 stars$4.64+14.9%$8.00+72.4%+41.0%$198.85MN/A-8.2920Upcoming EarningsNews CoverageGap DownHigh Trading VolumeIVAInventiva1.7885 of 5 stars$3.78-2.7%$10.40+174.8%+2.4%$198.57M$9.20M0.00100MDWDMediWound1.4521 of 5 stars$18.29+1.2%$31.33+71.3%-7.5%$197.68M$20.22M-6.3180Analyst ForecastNews CoverageELDNEledon Pharmaceuticals2.2493 of 5 stars$3.28+1.2%$12.50+281.1%+37.3%$196.41MN/A-1.6310Upcoming EarningsShort Interest ↑News CoverageCRDFCardiff Oncology1.4634 of 5 stars$2.95+2.4%$11.67+295.5%-19.9%$196.25M$683,000.00-3.1420News CoverageVYGRVoyager Therapeutics4.592 of 5 stars$3.53+1.7%$13.97+295.6%-58.7%$195.26M$80.00M4.97100Positive News Related Companies and Tools Related Companies Annexon Alternatives Ocugen Alternatives Y-mAbs Therapeutics Alternatives Gossamer Bio Alternatives DiaMedica Therapeutics Alternatives Inventiva Alternatives MediWound Alternatives Eledon Pharmaceuticals Alternatives Cardiff Oncology Alternatives Voyager Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PEPG) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PepGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PEPG Stock Free PEPG Stock Alerts